A Retrospective observational study of anti-CGRP drugs (erenumab, galcanezumab or fremanezumab) patients older than 65 years with chronic migraine or high-frequency episodic migraine
Latest Information Update: 08 Feb 2023
At a glance
- Drugs Erenumab (Primary) ; Fremanezumab (Primary) ; Galcanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 Feb 2023 New trial record
- 10 Dec 2022 Results presented at the 16th European headache federation COngress